Largest real-world effectiveness study of benralizumab for severe eosinophilic asthma: ZEPHYR 2.

Donna Carstens,Diego J Maselli,Fan Mu,Erin E Cook,Danni Yang,Joshua A Young,Keith A Betts,Eduardo Genofre,Yen Chung

The journal of allergy and clinical immunology. In practice（2023）

引用 2|浏览4

暂无评分

摘要

Benralizumab achieved significantly improved asthma control in real-world patients with different blood eosinophil counts, including eosinophil counts ranging from <150 to ≥300 cells/μl, switching from other biologics, or treated for up to 24 months.

查看译文

关键词

Severe eosinophilic asthma,Exacerbation,Real-world study,Benralizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要